PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “serogroup W”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1986

Gonorrhoea in heterosexual men. Correlation between gonococcal W serogroup, Chlamydia trachomatis infection and objective symptoms.

Among 292 heterosexual men with gonorrhoea seen during one year, 59 (20%), had a co-existing chlamydial infection. Of the men infected with a serogroup WI strain 30% had a chlamydial infection compared with 16% of those infected with a serogroup W II/III strain (p less than 0.01). Heterosexual men infected with WI strains had less objective symptoms as judged by the number of leucocytes per high power field and by discharge, than men infected with W II/III strains (p less than 0.05 and p less than 0.01, respectively).

Chlamydia Infections↗
PubMed1983

Gonococcal W serogroups in Scandinavia. A study with polyclonal and monoclonal antibodies.

A total of 849 gonococcal strains from 659 patients in Copenhagen (Denmark), Helsinki (Finland), Oslo and Trondheim (Norway) and Stockholm (Sweden) were included in the study. Using coagglutination reagents with polyclonal and monoclonal antibodies the strains were serogrouped into the previously described gonococcal serogroups W I, W II and W III. W II strains were dominating in all five towns (60.0%-70.9% of the strains), but W III strains were rarely isolated. W I strains were more frequent among women than among men. With the monoclonal reagents, W I, W II and W III strains could be further subdivided into 12, 29 and two different serovariants (serovars), respectively. One of the W I serovars was dominating (76%-94% of W I strains) in all five towns, and apart from this serovar, only three to five other W I serovars were seen in each town. Of W II strains, on the other hand, a greater variety of serovars were seen: between six in Trondheim and 17 in Oslo, and no one was dominating as among W I strains. Different W II serovar patterns were found in the different towns. Even between the two participating laboratories in each of the towns, Oslo and Helsinki, differences were noted. The epidemiological value of this is discussed. Ten of the 11 beta-lactamase-producing gonococcal strains isolated belonged to unusual serovars. None of the monoclonal coagglutination patterns corresponded to a single polyclonal pattern. There were, however, some relations between the two systems. In earlier studies it was shown that in smaller Swedish towns W I strains dominated. A hyphothesis about protective anti-Protein I antibodies is discussed to explain the differences in distribution of W I and W II strains between smaller and larger towns and between women and men.

Adolescent↗
PubMed1980

Acute septic arthritis caused by Neisseria meningitidis serogroup W-135.

Neisseria meningitidis, serogroup W-135 was isolated from blood cultures of a 22-month-old child with acute septic arthritis of the left knee. Recovery was complete after treatment with penicillin G. Acute septic arthritis may be the initial presentation of disease caused by Neisseria meningitidis serogroup W-135.

Acute Disease↗
PubMed2003

Serogroup W-135 meningococcal disease during the Hajj, 2000.

An outbreak of serogroup W-135 meningococcal disease occurred during the 2000 Hajj in Saudi Arabia. Disease was reported worldwide in Hajj pilgrims and their close contacts; however, most cases were identified in Saudi Arabia. Trends in Saudi meningococcal disease were evaluated and the epidemiology of Saudi cases from this outbreak described. Saudi national meningococcal disease incidence data for 1990 to 2000 were reviewed; cases from January 24 to June 5, 2000, were retrospectively reviewed. The 2000 Hajj outbreak consisted of distinct serogroup A and serogroup W-135 outbreaks. Of 253 identified cases in Saudi Arabia, 161 (64%) had serogroup identification; serogroups W-135 and A caused 93 (37%) and 60 (24%) cases with attack rates of 9 and 6 cases per 100,000 population, respectively. The 2000 Hajj outbreak was the first large serogroup W-135 meningococcal disease outbreak identified worldwide. Enhanced surveillance for serogroup W-135, especially in Africa, is essential to control this emerging epidemic disease.

Anniversaries and Special Events↗
PubMed2004

Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj.

In 2000, a large international outbreak of meningococcal disease caused by Neisseria meningitidis serogroup W-135 was identified among pilgrims returning from the Hajj in Saudi Arabia. To assess ongoing risk, we evaluated N. meningitidis carriage among US travelers to the 2001 Hajj. Of 25 N. meningitidis isolates obtained, 15 (60%) were nongroupable and 8 (32%) were serogroup W-135 when tested by standard slide-agglutination techniques. Two additional nongroupable isolates were characterized as serogroup W-135 when tested by polymerase chain reaction. Nine of 10 serogroup W-135 isolates were indistinguishable from the Hajj-2000 clone. None of the departing, but 9 (1.3%) of the returning, pilgrims carried serogroup W-135 (P=.01); all carriers reported previous vaccination. Carriage of N. meningitidis serogroup W-135 increased significantly in pilgrims returning from the Hajj. Although the risk of disease to pilgrims appears to be low, the risk of spread to others of this pathogenic strain remains a concern.

Adult↗
PubMed2003

Neisseria meningitidis serogroup W-135 isolated from healthy carriers and patients in Sudan after the Hajj in 2000.

The first epidemic in the world of meningococcal disease due to serogroup W-135 was reported during the Hajj in 2000, with subsequent spread. The aims of the present study were to investigate whether the Hajj 2000 Neisseria meningitidis serogroup W-135 had also been carried to Sudan in the eastern part of the African meningitis belt, by examining healthy Sudanese pilgrims (Hajj 2000) and members of their families, and whether the strain was causing meningitis. The phenotypic character of W-135 meningococci from Sudanese carriers (n = 5) and patients (n = 2) 1 y later was similar to W-135 strains associated with Hajj 2000. The present study, using the combination of the 2 molecular techniques; sequencing of the porA gene for variable regions (VR1, VR2 and VR3) and pulsed-field gel electrophoresis of the entire genome (using SpeI and NheI), shows that the Hajj 2000 serogroup W-135 clone (P1.5,2,36-2 of the ET-37 complex) most probably was introduced into Sudan, by pilgrims returning from the Hajj 2000. This strain has not been diagnosed before in Sudan. Close epidemiological surveillance is required to identify a possible new emerging meningitis epidemic.

Adolescent↗
PubMed1990

Disease in children due to serogroup W-135 Neisseria meningitidis.

Two cases of meningococcal disease due to serogroup W-135 Neisseria meningitidis are presented. One died from fulminating meningococcaemia and the other had severe meningoencephalitis with acute septic arthritis. Serogroup W-135 N. meningitidis is pathogenic for man, and laboratories should attempt to identify and serotype the organism so that more data about the disease it causes can be obtained.

Child↗
PubMed2000

Carriage of serogroup W-135, ET-37 meningococci in The Gambia: implications for immunisation policy?

We found high levels of symptomless carriage of a hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40% of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0%. The recent Haj-associated spread of serogroup W-135, ET-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.

Bacterial Vaccines↗
PubMed2006

Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002.

BACKGROUND: The African meningitis belt undergoes recurrent epidemics caused by Neisseria meningitidis serogroup A. During 2002, Burkina Faso documented the first large serogroup W-135 (NmW-135) meningococcal disease epidemic. To understand the emergence of NmW-135, we investigated meningococcal carriage and immunity. METHODS: Immediately after Burkina Faso's epidemic, we conducted a cross-sectional survey of meningococcal carriage and seroprevalence in an epidemic and a nonepidemic district. We identified predictors of elevated NmW-135 serum bactericidal activity (SBA), a functional correlate of protection, using multivariate logistic regression. RESULTS: The NmW-135 carriage rate was 25.2% in the epidemic district and 3.4% in the nonepidemic district (P<.0001). Compared with residents of the nonepidemic district, those of the epidemic district had higher geometric mean titers of NmW-135 SBA (P<.0001). NmW-135 SBA titers>or=1:8, an estimated protective threshold, were observed in 60.4% and 34.0% of residents of the epidemic and nonepidemic district, respectively (P=.0002). In a multivariate model, current NmW-135 carriage, age, and residence in the epidemic district were independent predictors of having an NmW-135 SBA titer>or=1:8. CONCLUSIONS: Extensive NmW-135 carriage and transmission in the epidemic area caused residents to acquire natural immunity. Serial carriage and seroprevalence surveys could establish the duration of immunity in the population. The persistent circulation of NmW-135 underscores the potential for periodic NmW-135 epidemics in Africa.

Adolescent↗
PubMed2001

Comparison of serogroup W-135 meningococci isolated in Sweden during a 23-year period and those associated with a recent hajj pilgrimage.

An outbreak of serogroup W-135 meningococcal disease was reported among pilgrims returning from the annual hajj (pilgrimage to Mecca) in mid-March 2000. Molecular characterization was used to investigate the similarity of the hajj-associated W-135 strains with those isolated in Sweden during a 23-year period (1978 to 2000). The same hajj-associated genosubtype, genosubtype P1.5,2,36b, has been documented in Sweden since 1979, while pulsed-field gel electrophoresis and the sulfadiazine resistance of the W-135 isolates indicated that the outbreak was probably due to a new clone of W-135 meningococci.

Disease Outbreaks↗
PubMed1981

Neisseria meningitidis serogroup W 135 disease in adults.

Five adults had infection caused by Neisseria meningitidis serogroup W135. Their ages ranged from 19 to 74 years, and the spectrum of illness included meningitis, pneumonia, and acute peritonitis. Two patients had systemic lupus erythematosus and were receiving corticosteroids at the time of their infection. One patient died of fulminant meningococcemia. All isolates were sensitive to sulfonamides. The recent increase in the national incidence of N meningitidis serogroup W135 infections emphasizes the need for continuing surveillance and justifies its inclusion in a polyvalent meningococcal vaccine.

Adult↗
PubMed2000

Neisseria meningitidis serogroup W-135 primary monarthritis of the hip in an immunocompetent child.

Reported here is the first known case of primary monoarthritis of the hip due to Neisseria meningitidis W-135. The isolate was obtained from an immunocompetent child suffering from acute hip pain as the only symptom upon presentation at the hospital. Meningococcal infection must be considered in the diagnosis of any child presenting with arthritis, even if afebrile and without rash.

Adolescent↗
PubMedDate not supplied

Use of gonococcal W serogrouping in the evaluation of a clinical trial of rosoxacin.

Serogrouping by co-agglutination was used for the characterization of isolates of Neisseria gonorrhoeae in a clinical trial of rosoxacin in Stockholm. Twenty-four isolates (56%) belonged to serogroup WI, 17 (40%) to WII, and two (5%) to WIII. The proportion of WI isolates in Stockholm was reported in earlier studies to be approximately 40%. On the basis of serogrouping data and clinical information, five (10%) of 48 patients in this study were classified as therapeutic failures. Of the initial WI isolates, 22 (92%) of 24 were inhibited by less than or equal to 0.03 microgram of rosoxacin/ml, as compared with ten (59%) of 17 of the initial WII isolates (.05 greater than P greater than .01). Thus, this study might underestimate the failure rate as compared with that for patient populations in which WII isolates are more prevalent, since WI isolates are more susceptible to rosoxacin than WII isolates. A certain WII serovar was correlated with decreased susceptibility to rosoxacin (P less than .001). Correlations were found between decreased susceptibility to rosoxacin and decreased susceptibility to other antibiotics (P less than or equal to .01). A high frequency of side effects (40%) was seen among the patients studied.

4-Quinolones↗